David Dai
Stock Analyst at UBS
(0.42)
# 4,022
Out of 4,876 analysts
23
Total ratings
21.05%
Success rate
-28.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Dai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BPMC Blueprint Medicines | Maintains: Neutral | $88 → $129 | $128.11 | +0.69% | 2 | Jun 5, 2025 | |
| IOVA Iovance Biotherapeutics | Downgrades: Neutral | $17 → $2 | $1.69 | +18.34% | 2 | May 16, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Buy | $30 → $24 | $7.76 | +209.28% | 2 | May 12, 2025 | |
| NUVL Nuvalent | Upgrades: Buy | $100 | $79.68 | +25.50% | 2 | Mar 14, 2025 | |
| KURA Kura Oncology | Maintains: Buy | $27 → $14 | $5.67 | +146.91% | 2 | Mar 6, 2025 | |
| IMCR Immunocore Holdings | Initiates: Sell | $24 | $31.15 | -22.95% | 1 | Oct 24, 2024 | |
| CATX Perspective Therapeutics | Initiates: Buy | $20 | $3.76 | +431.91% | 1 | Oct 24, 2024 | |
| NRIX Nurix Therapeutics | Initiates: Buy | $35 | $11.64 | +200.69% | 1 | Oct 24, 2024 | |
| MRUS Merus | Initiates: Buy | $72 | $52.95 | +35.98% | 1 | Oct 24, 2024 | |
| JANX Janux Therapeutics | Initiates: Buy | $69 | $23.15 | +198.06% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $21.37 | +133.97% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $25.95 | +131.21% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $9.03 | +309.97% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $0.63 | +4,375.70% | 1 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $14.43 | +177.20% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $1.19 | +3,261.34% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $1.66 | +2,912.05% | 1 | Nov 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $41 → $52 | $33.07 | +57.24% | 1 | Mar 17, 2020 |
Blueprint Medicines
Jun 5, 2025
Maintains: Neutral
Price Target: $88 → $129
Current: $128.11
Upside: +0.69%
Iovance Biotherapeutics
May 16, 2025
Downgrades: Neutral
Price Target: $17 → $2
Current: $1.69
Upside: +18.34%
Cullinan Therapeutics
May 12, 2025
Maintains: Buy
Price Target: $30 → $24
Current: $7.76
Upside: +209.28%
Nuvalent
Mar 14, 2025
Upgrades: Buy
Price Target: $100
Current: $79.68
Upside: +25.50%
Kura Oncology
Mar 6, 2025
Maintains: Buy
Price Target: $27 → $14
Current: $5.67
Upside: +146.91%
Immunocore Holdings
Oct 24, 2024
Initiates: Sell
Price Target: $24
Current: $31.15
Upside: -22.95%
Perspective Therapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $20
Current: $3.76
Upside: +431.91%
Nurix Therapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $35
Current: $11.64
Upside: +200.69%
Merus
Oct 24, 2024
Initiates: Buy
Price Target: $72
Current: $52.95
Upside: +35.98%
Janux Therapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $69
Current: $23.15
Upside: +198.06%
Oct 24, 2024
Initiates: Buy
Price Target: $50
Current: $21.37
Upside: +133.97%
Oct 24, 2024
Initiates: Buy
Price Target: $60
Current: $25.95
Upside: +131.21%
Oct 24, 2024
Initiates: Buy
Price Target: $37
Current: $9.03
Upside: +309.97%
Mar 31, 2022
Initiates: Outperform
Price Target: $28
Current: $0.63
Upside: +4,375.70%
Mar 16, 2022
Initiates: Outperform
Price Target: $40
Current: $14.43
Upside: +177.20%
Feb 4, 2022
Initiates: Outperform
Price Target: $40
Current: $1.19
Upside: +3,261.34%
Nov 18, 2021
Initiates: Outperform
Price Target: $50
Current: $1.66
Upside: +2,912.05%
Mar 17, 2020
Upgrades: Outperform
Price Target: $41 → $52
Current: $33.07
Upside: +57.24%